Magic mushroom API synthesized for Worldwide Clinical Trials study

By Flora Southey contact

- Last updated on GMT


Related tags: Clinical trial

Compass Pathways has selected Worldwide Clinical Trials to conduct studies of its investigational psychoactive therapy, designed for patients with treatment-resistant depression.

The trials will test the efficacy and safety of the investigational psilocybin therapy – made with a synthesized version​ of an active ingredient in magic mushrooms – across sites in the Czech Republic, Finland, Germany, the Netherlands, Portugal, Spain and the UK.

Psychedelic or ‘magic’ mushrooms contain various psychedelic compounds, including psilocybin.

Compass told us it is working with Worldwide Clinical Trials to implement a patient-centric approach.

“All our partners and suppliers have been involved in mapping out the full clinical trial process, thinking about the patient journey and patient impact at every step,” ​spokesperson Tracy Cheung told us.

The firm will educate patients prior to the trial, and will have trained therapists on-hand to accompany patients throughout the study, said Cheung.

“We have invested a great deal of effort in developing psychoeducational materials that will be shared online with prospective patients…this will help patients to learn more about psilocybin therapy and ensure that all patients are well prepared for the treatment session,” ​she added.

According to Compass, patient recorded outcomes (PROs) will help assess the efficacy and safety of the synthesized psilocybin product. 

“Data will be entered by patients into an electronic portal on a tablet available at the investigational site,” ​Cheung told us, adding that all data will be consolidated for analysis and review.

Recruitment and psychoactive effects

Cheung said although the main challenge for a clinical trial is usually the recruitment of eligible patients, she believes this trial will attract sufficient numbers.

“We are offering a potential therapy for the indication where there is unmet medical need, so we believe interest will be high,” ​she told us.

According to Cheung, recruited patients will experience psychoactive effects, but will be under close supervision while undergoing the therapy.

“We are expecting trial patients to experience psychedelic – that is psychoactive effects – since psilocybin is a psychoactive drug,” ​she told us.

“Based on experience from previous studies, this might be a predictor of efficacy and improvement sustainability,” ​she added.

Patient recruitment will begin next year at a number of sites across Europe, the same year the firm hopes to file an investigational new drug (IND) application with the US Food and Drug Administration (FDA), we were told.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us


View more